P.468 Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study by Satlin, A., Durgam, S., Vanover, K.E., Davis, R.E., Chen, R., Mates, S., Correll, C.U.

Get full text

P.671 Efficacy and safety of lumateperone tosylate 42mg in the treatment of schizophrenia: A pooled analysis of phase 2 and 3 studies by Kane, J.M., Vanover, K.E., Durgam, S., Weingart, M., Davis, R., Satlin, A., Tamminga, C.

Get full text

P.673 Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia by Correll, C.U., Vanover, K.E., Durgam, S., Weingart, M., Davis, R., Satlin, A.

Get full text

P.446 Efficacy and safety of lumateperone (ITI-007) in the treatment of depressive episodes associated with bipolar I and II disorders by Durgam, S., Satlin, A., Vanover, K.E., Davis, R.E., Edwards, J.B., Kozauer, S.G., Huo, J., Mates, S., Calabrese, J.R.

Get full text

Unique antipsychotic profile of a novel 5-HT2A receptor antagonist and dopamine receptor protein phosphorylation modulator by Wennogle, L.P, Snyder, G.L, Hendrick, J.P, Vanover, K.E, Tomesch, J.T, Li, P, O'callaghan, J.P, Miller, D.B, Fienberg, A.A, Davis, R.E, Mates, S

Get full text

5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics by Weiner, D.M., Burstein, E.S., Nash, N., Croston, G.E., Currier, E.A., Vanover, K.E., Harvey, S.C., Donohue, E., Hansen, H.C., Andersson, C.M., Spalding, T.A., Gibson, D.F.C., Krebs-Thomson, K., Powell, S.B., Geyer, M.A., Hacksell, U., Brann, M.R.

Get full text

Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders by Vanover, K.E., O’Gorman, C., Correll, C.U., Glass, S., Mates, S., Saillard, J., Weingart, M., Davis, R.

Get full text

P.1.g.038 - Lumateperone (ITI-007): a novel investigational agent with broad therapeutic potential across multiple neuropsychiatric disorders by Vanover, K.E., O’Gorman, C., Correll, C.U., Glass, S., Mates, S., Saillard, J., Weingart, M., Davis, R.

Get full text

Unique antipsychotic profile of a novel 5-HT 2A receptor antagonist and dopamine receptor protein phosphorylation modulator by Wennogle, L.P., Snyder, G.L., Hendrick, J.P., Vanover, K.E., Tomesch, J.T., Li, P., O'callaghan, J.P., Miller, D.B., Fienberg, A.A., Davis, R.E., Mates, S.

Get full text

III.P5 ACP-103 Reduces psychosis without impairing motor function in Parkinson's Disease by van Kammen, D.P., Taylor, E.M., Weiner, D.M., Vanover, K.E., Davis, R.E.

Get full text

ACP-103, A 5-HT2A receptor inverse agonist, a novel potential treatment for psychosis by Vanover, K.E., Weiner, D.M., Harvey, S.C., Powell, S.B., Geyer, M.A., Andersson, C.M., Tolf, B.R., Hacksell, U., Brann, M.R., Davis, R.E.

Get full text